Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
41
SAVA Quote, Financials, Valuation and Earnings
Last price:
$3.33
Seasonality move
:
28.64%
Day range:
$3.06 - $3.35
52-week range:
$1.15 - $4.98
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.69x
P/B ratio:
1.97x
Volume:
1.1M
Avg. volume:
1.2M
1-year change:
12.54%
Market cap:
$160.4M
Revenue:
--
EPS (TTM):
-$2.20
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SAVA
Cassava Sciences, Inc.
|
-- | -$0.68 | -- | -36% | $8.00 |
|
BIIB
Biogen, Inc.
|
$2.3B | $3.88 | -5.34% | -4.29% | $178.76 |
|
GERN
Geron Corp.
|
$53.3M | -$0.04 | 7.03% | -8.38% | $3.50 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
OVID
Ovid Therapeutics, Inc.
|
$170.4K | -$0.15 | 2.96% | -25.17% | $4.19 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SAVA
Cassava Sciences, Inc.
|
$3.32 | $8.00 | $160.4M | -- | $0.00 | 0% | 2.69x |
|
BIIB
Biogen, Inc.
|
$181.98 | $178.76 | $26.7B | 16.60x | $0.00 | 0% | 2.75x |
|
GERN
Geron Corp.
|
$1.27 | $3.50 | $810.7M | -- | $0.00 | 0% | 4.61x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$1.09 | $0.85 | $137.4M | 1.83x | $0.80 | 0% | 2.12x |
|
OVID
Ovid Therapeutics, Inc.
|
$1.62 | $4.19 | $115.4M | -- | $0.00 | 0% | 17.42x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SAVA
Cassava Sciences, Inc.
|
-- | 4.880 | -- | 2.21x |
|
BIIB
Biogen, Inc.
|
26.58% | 0.737 | 32.07% | 1.77x |
|
GERN
Geron Corp.
|
50.25% | 1.700 | 28.73% | 4.76x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
OVID
Ovid Therapeutics, Inc.
|
23.54% | 4.091 | 14.88% | 3.77x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SAVA
Cassava Sciences, Inc.
|
-$200K | -$11.9M | -86.98% | -86.98% | -- | -$6.3M |
|
BIIB
Biogen, Inc.
|
$1.6B | $613.8M | 6.76% | 9.36% | 25% | $1.2B |
|
GERN
Geron Corp.
|
$45.9M | -$13.9M | -16.45% | -29.65% | -29.41% | -$13.5M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
OVID
Ovid Therapeutics, Inc.
|
$115K | -$12.5M | -48.14% | -59.7% | -9487.12% | -$12.9M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
Cassava Sciences, Inc. vs. Competitors
-
Which has Higher Returns SAVA or BIIB?
Biogen, Inc. has a net margin of -- compared to Cassava Sciences, Inc.'s net margin of 19%. Cassava Sciences, Inc.'s return on equity of -86.98% beat Biogen, Inc.'s return on equity of 9.36%.
Company Gross Margin Earnings Per Share Invested Capital SAVACassava Sciences, Inc.-- -$0.22 $81.6M BIIBBiogen, Inc.64.29% $3.17 $24.8B -
What do Analysts Say About SAVA or BIIB?
Cassava Sciences, Inc. has a consensus price target of $8.00, signalling upside risk potential of 140.96%. On the other hand Biogen, Inc. has an analysts' consensus of $178.76 which suggests that it could fall by -1.77%. Given that Cassava Sciences, Inc. has higher upside potential than Biogen, Inc., analysts believe Cassava Sciences, Inc. is more attractive than Biogen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SAVACassava Sciences, Inc.1 0 0 BIIBBiogen, Inc.14 19 0 -
Is SAVA or BIIB More Risky?
Cassava Sciences, Inc. has a beta of -1.081, which suggesting that the stock is 208.123% less volatile than S&P 500. In comparison Biogen, Inc. has a beta of 0.128, suggesting its less volatile than the S&P 500 by 87.226%.
-
Which is a Better Dividend Stock SAVA or BIIB?
Cassava Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cassava Sciences, Inc. pays -- of its earnings as a dividend. Biogen, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SAVA or BIIB?
Cassava Sciences, Inc. quarterly revenues are --, which are smaller than Biogen, Inc. quarterly revenues of $2.5B. Cassava Sciences, Inc.'s net income of -$10.8M is lower than Biogen, Inc.'s net income of $466.5M. Notably, Cassava Sciences, Inc.'s price-to-earnings ratio is -- while Biogen, Inc.'s PE ratio is 16.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cassava Sciences, Inc. is 2.69x versus 2.75x for Biogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SAVACassava Sciences, Inc.2.69x -- -- -$10.8M BIIBBiogen, Inc.2.75x 16.60x $2.5B $466.5M
-
Which has Higher Returns SAVA or GERN?
Geron Corp. has a net margin of -- compared to Cassava Sciences, Inc.'s net margin of -39.02%. Cassava Sciences, Inc.'s return on equity of -86.98% beat Geron Corp.'s return on equity of -29.65%.
Company Gross Margin Earnings Per Share Invested Capital SAVACassava Sciences, Inc.-- -$0.22 $81.6M GERNGeron Corp.97.13% -$0.03 $500M -
What do Analysts Say About SAVA or GERN?
Cassava Sciences, Inc. has a consensus price target of $8.00, signalling upside risk potential of 140.96%. On the other hand Geron Corp. has an analysts' consensus of $3.50 which suggests that it could grow by 162.47%. Given that Geron Corp. has higher upside potential than Cassava Sciences, Inc., analysts believe Geron Corp. is more attractive than Cassava Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SAVACassava Sciences, Inc.1 0 0 GERNGeron Corp.3 2 1 -
Is SAVA or GERN More Risky?
Cassava Sciences, Inc. has a beta of -1.081, which suggesting that the stock is 208.123% less volatile than S&P 500. In comparison Geron Corp. has a beta of 0.567, suggesting its less volatile than the S&P 500 by 43.26%.
-
Which is a Better Dividend Stock SAVA or GERN?
Cassava Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cassava Sciences, Inc. pays -- of its earnings as a dividend. Geron Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SAVA or GERN?
Cassava Sciences, Inc. quarterly revenues are --, which are smaller than Geron Corp. quarterly revenues of $47.2M. Cassava Sciences, Inc.'s net income of -$10.8M is higher than Geron Corp.'s net income of -$18.4M. Notably, Cassava Sciences, Inc.'s price-to-earnings ratio is -- while Geron Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cassava Sciences, Inc. is 2.69x versus 4.61x for Geron Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SAVACassava Sciences, Inc.2.69x -- -- -$10.8M GERNGeron Corp.4.61x -- $47.2M -$18.4M
-
Which has Higher Returns SAVA or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Cassava Sciences, Inc.'s net margin of -255.85%. Cassava Sciences, Inc.'s return on equity of -86.98% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital SAVACassava Sciences, Inc.-- -$0.22 $81.6M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About SAVA or NBY?
Cassava Sciences, Inc. has a consensus price target of $8.00, signalling upside risk potential of 140.96%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -22.02%. Given that Cassava Sciences, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Cassava Sciences, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SAVACassava Sciences, Inc.1 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is SAVA or NBY More Risky?
Cassava Sciences, Inc. has a beta of -1.081, which suggesting that the stock is 208.123% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock SAVA or NBY?
Cassava Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Cassava Sciences, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SAVA or NBY?
Cassava Sciences, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Cassava Sciences, Inc.'s net income of -$10.8M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Cassava Sciences, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cassava Sciences, Inc. is 2.69x versus 2.12x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SAVACassava Sciences, Inc.2.69x -- -- -$10.8M NBYNovaBay Pharmaceuticals, Inc.2.12x 1.83x $521K -$1.3M
-
Which has Higher Returns SAVA or OVID?
Ovid Therapeutics, Inc. has a net margin of -- compared to Cassava Sciences, Inc.'s net margin of -9210.61%. Cassava Sciences, Inc.'s return on equity of -86.98% beat Ovid Therapeutics, Inc.'s return on equity of -59.7%.
Company Gross Margin Earnings Per Share Invested Capital SAVACassava Sciences, Inc.-- -$0.22 $81.6M OVIDOvid Therapeutics, Inc.87.12% -$0.17 $58.5M -
What do Analysts Say About SAVA or OVID?
Cassava Sciences, Inc. has a consensus price target of $8.00, signalling upside risk potential of 140.96%. On the other hand Ovid Therapeutics, Inc. has an analysts' consensus of $4.19 which suggests that it could grow by 158.41%. Given that Ovid Therapeutics, Inc. has higher upside potential than Cassava Sciences, Inc., analysts believe Ovid Therapeutics, Inc. is more attractive than Cassava Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SAVACassava Sciences, Inc.1 0 0 OVIDOvid Therapeutics, Inc.9 0 0 -
Is SAVA or OVID More Risky?
Cassava Sciences, Inc. has a beta of -1.081, which suggesting that the stock is 208.123% less volatile than S&P 500. In comparison Ovid Therapeutics, Inc. has a beta of 0.045, suggesting its less volatile than the S&P 500 by 95.453%.
-
Which is a Better Dividend Stock SAVA or OVID?
Cassava Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ovid Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cassava Sciences, Inc. pays -- of its earnings as a dividend. Ovid Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SAVA or OVID?
Cassava Sciences, Inc. quarterly revenues are --, which are smaller than Ovid Therapeutics, Inc. quarterly revenues of $132K. Cassava Sciences, Inc.'s net income of -$10.8M is higher than Ovid Therapeutics, Inc.'s net income of -$12.2M. Notably, Cassava Sciences, Inc.'s price-to-earnings ratio is -- while Ovid Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cassava Sciences, Inc. is 2.69x versus 17.42x for Ovid Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SAVACassava Sciences, Inc.2.69x -- -- -$10.8M OVIDOvid Therapeutics, Inc.17.42x -- $132K -$12.2M
-
Which has Higher Returns SAVA or PTN?
Palatin Technologies has a net margin of -- compared to Cassava Sciences, Inc.'s net margin of --. Cassava Sciences, Inc.'s return on equity of -86.98% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SAVACassava Sciences, Inc.-- -$0.22 $81.6M PTNPalatin Technologies-- -- -- -
What do Analysts Say About SAVA or PTN?
Cassava Sciences, Inc. has a consensus price target of $8.00, signalling upside risk potential of 140.96%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Cassava Sciences, Inc., analysts believe Palatin Technologies is more attractive than Cassava Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SAVACassava Sciences, Inc.1 0 0 PTNPalatin Technologies0 0 0 -
Is SAVA or PTN More Risky?
Cassava Sciences, Inc. has a beta of -1.081, which suggesting that the stock is 208.123% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock SAVA or PTN?
Cassava Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cassava Sciences, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SAVA or PTN?
Cassava Sciences, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Cassava Sciences, Inc.'s net income of -$10.8M is higher than Palatin Technologies's net income of --. Notably, Cassava Sciences, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cassava Sciences, Inc. is 2.69x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SAVACassava Sciences, Inc.2.69x -- -- -$10.8M PTNPalatin Technologies-- -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 18.9% over the past day.
